Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9BYN7
UPID:
ZN341_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BYN7; A2RUF4; B2RXE5; B7ZM09; Q5JXM8; Q96ST5
Background:
Zinc finger protein 341, identified by the accession number Q9BYN7, plays a pivotal role in immune regulation. It functions as a transcriptional activator of STAT3, crucial for maintaining immune homeostasis. Additionally, it can activate STAT1 transcription, underscoring its versatile role in immune responses.
Therapeutic significance:
The protein is linked to Hyper-IgE recurrent infection syndrome 3, an autosomal recessive disorder. This connection highlights its potential as a target for therapeutic intervention in immune-related diseases. Understanding the role of Zinc finger protein 341 could open doors to potential therapeutic strategies.